🍌 $FNGR (FingerMotion) filed an S-1 · Jun 11, 17:30 ET Registers 16.5M Shares for Resale from Dilutive $5M Secured Convertible Note; Secures Final $1M Tranche Filed at $0.6121 → Now $0.4791 (-21.7%) Banancial breakdown 👇 🔴 Score 8/10 Source: Wiseek (link in bio)

🍌 We peeled $JVA (Coffee Holding CO)'s 8-K · Jun 12, 16:20 ET . Reports 59% Drop in Q2 Net Income Amid Green Coffee Price Declines Filed at $4.27 → Now $3.82 (-10.6%) Watch the breakdown 👇 🔴 Score 8/10 Source: Wiseek (link in bio)

🍌 $CIIT (Tianci International) filed an S-1/A · Jun 12, 16:51 ET Amends S-1 for Highly Dilutive $6M Unit Offering with Punitive Warrants Filed at $1.79 → Now $1.60 (-10.6%) Banancial breakdown 👇 🔴 Score 9/10 Source: Wiseek (link in bio)

🍌 $AIHS (Senmiao Technology) · 8-K filed Jun 12, 16:05 ET Shareholders Approve Massive Dilution, Reverse Stock Split, and $11M Private Placement Filed at $1.36 → Now $1.17 (-14.0%) Full breakdown 👇 🔴 Score 9/10 Source: Wiseek (link in bio)

🍌 We peeled $DTSS (Datasea Intelligent Technology)'s 6-K · Jun 12, 17:15 ET Datasea Subsidiary Acquires Cloud Detection Patent for $1.03M, to Pay with New Shares Filed at $1.02 → Now $0.8700 (-14.7%) Watch the breakdown 👇 🔴 Score 8/10 Source: Wiseek (link in bio)

🍌 $BYAH (Park Ha Biological Technology Co.) · news · Jun 12, 14:54 ET Park Ha Biotech Prices $2M Offering at 17% Discount, Signaling Urgent Capital Need Reported at $1.80 → Now $1.39 (-23.0%) Banancial breakdown 👇 🔴 Score 9/10 Source: Wiseek (link in bio)

🍌 $BBGI (Beasley Broadcast Group) filed a 424B5 · Jun 12, 15:04 ET Initiates $5.2M At-The-Market Offering, Potentially Diluting Shareholders by 12.9% Filed at $22.42 → Now $16.56 (-26.1%) Banancial breakdown 👇 🔴 Score 8/10 Source: Wiseek (link in bio)

🍌 We peeled $RUBI (Rubico)'s 6-K · Jun 12, 15:18 ET Secures $4.8M by Inducing Warrant Exercise, Issues New Warrants for 200% of Shares Filed at $0.8028 → Now $0.4935 (-38.5%) Watch the breakdown 👇 🔴 Score 9/10 Source: Wiseek (link in bio)

$BYAH — just secured $2.0 million in working capital, but at a punishing cost to shareholders. This registered direct offering, priced at a steep discount, draws from their existing $300 million universal shelf. We peeled this 6-K right when it hit. The terms are telling: BYAH sold shares at $1.50 each, a roughly 14% discount from the $1.7407 market price at the time of filing. This isn't just a small raise; it represents over 35% dilution relative to the company's current market capitalization. Such significant concessions point to a pressing need for funds, forcing the company to accept unfavorable pricing. Investors should brace for downward pressure. This move signals urgency for capital rather than strong negotiating power. It's a clear trade-off: liquidity now for substantial shareholder dilution later. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$BKYI — A 'going concern' warning just hit for BKYI in its latest 10-K, signaling severe financial distress and imminent Nasdaq delisting. We peeled this filing immediately. The auditor's red flag is definitive, coupled with a substantial investment impairment and mounting losses that validate the operational challenges. Cash burn is accelerating, painting a stark picture of a company struggling for viability. Despite raising capital through dilutive warrant exercises and secured notes, these funds merely offset the growing deficits. This wasn't growth capital; it was a necessary lifeline that came with significant shareholder dilution. With the stock trading at $3.945 at the time of filing, the market is now processing the full gravity of this official report. We'll be scrutinizing debt covenant compliance, authorized vs. outstanding share counts, and any future guidance. This 10-K establishes a grim financial baseline. The path to profitability and a potential relisting remains highly uncertain. Headlines are late. Filings aren't. Source & full breakdown: Wiseek (link in bio)

$INHD — Nasdaq just halted trading of INHD shares due to unusual activity. At $39.49 at filing, this isn't a minor regulatory check; it's a serious red flag. We peeled this 8-K, which details the formation of a special committee to investigate, despite the company claiming no material undisclosed developments. This halt comes while INNO Holdings is already managing significant 'going concern' issues and actively utilizing a $60 million At-The-Market offering we flagged back in May. The new special committee adds another layer of uncertainty to a company that just last week announced a $3 million investment into an AI sales system. Investors are facing increased risk as this independent investigation unfolds. Headlines are late. Filings aren't. Source & full breakdown: Wiseek (link in bio)

$IONS — Ionis Pharmaceuticals just solidified a key pipeline asset. IONS reported positive 24-month data for olezarsen in severe hypertriglyceridemia, demonstrating sustained hepatic fat reduction and a favorable safety profile. This isn't just a win; it's a significant de-risking event for a drug with substantial commercial potential. High patient retention in the study points to real-world tolerability. We peeled this filing immediately after the 18:20 UTC drop at $73.19. This long-term validation builds on recent positive reports and reinforces the drug's path to regulatory approval and future commercial success. IONS's Q1 showed robust sales and reduced net loss; this data strengthens future revenue projections, mitigating some pipeline risk. However, it’s worth noting the consistent $26.8M insider distribution over the last 90 days. While the clinical news is bullish, the insiders’ conviction on market activity presents a contrasting signal. The market often gets caught up in the headlines. This 8-K gives us the hard data confirming a stronger drug profile for olezarsen. We've seen the 12-month updates; this 24-month data solidifies the investment thesis. Headlines are late. Filings aren't. Source & full breakdown: Wiseek (link in bio)

$LHAI — Linkhome Holdings is pushing for a reverse stock split to cling to its Nasdaq listing. This isn't just about the $0.775 stock price. It's a clear distress signal we've seen coming. We previously flagged their ineffective disclosure controls and high cash burn in the amended Q1 filing. Now, shareholders are being asked to approve a reverse split to avoid delisting, a common move for struggling microcaps. But here’s the kicker: Concurrently, they propose a new equity incentive plan. This isn't just a survival tactic; it's a potential dilution bomb for existing shareholders, layered on top of a desperate stock split. Insiders already showed their hand, unloading $2.37 million in shares over the last 90 days, signaling a lack of confidence. This PRE 14A confirms the bearish sentiment. A reverse split rarely stabilizes a sinking ship, especially when management is simultaneously setting up massive new share issuance capacity. Expect continued pressure on LHAI as the market digests this double whammy of a listing fight and fresh dilution risk. Headlines are late. Filings aren't. Source & full breakdown: Wiseek (link in bio)

🍌 $AKAN (Akanda) filed a 6-K · Jun 12, 08:00 ET Regains Nasdaq Compliance, Resolving Delisting Risk Filed at $15.35 → Now $19.20 ( 25.1%) Banancial breakdown 👇 🟢 Score 8/10 Source: Wiseek (link in bio)

$JCTC — An activist investor group just upped its stake in JCTC to 9.4% of outstanding shares. This isn't a passive hold. We caught this 13D/A detailing continued open market purchases, signaling conviction at the filing price of $2.03. This group, led by Adam Bradley, previously held 8.2% and is not backing down. This increased investment comes as Jewett Cameron is facing a 'going concern' warning from its last 10-Q, having reported a widened net loss and collapsed gross margins. The activist group explicitly states its intent to engage management and the board to propose significant changes to capitalization, ownership, board structure, and operational performance. This isn't a subtle nudge; it's a direct push for strategic improvements where they're desperately needed. Watch for escalating engagement and concrete proposals to emerge. The activist clearly believes the shares are undervalued and is increasing pressure to unlock that value amidst the company's struggles. Headlines are late. Filings aren't. Source & full breakdown: Wiseek (link in bio)

$NROM — just wiped out a major financial overhang. The critical debt maturity we flagged in its recent 10-K is now history. This 8-K confirms a significant turnaround in their financial position. We peeled this 8-K: Noble Roman's secured a new $6.9 million, five-year senior secured term loan. This isn't just new money; it's a critical refinancing with more favorable, non-dilutive terms, replacing the burdensome June 2026 maturity. Subordinated debt has been repaid, and 5.5 million outstanding warrants were redeemed. That's a massive overhang removed, enhancing their capital structure and providing crucial stability for the company. The market was pricing NROM at $0.5 at filing time. Headlines are late. Filings aren't. Source & full breakdown: Wiseek (link in bio)

$DBGI — CEO just plunged an *additional* $700,000 of personal capital into company stock. This open market purchase at $0.9137 per share brings John Hilburn Davis IV's total recent investment to nearly $750,000 in days. We’re talking about over 3% of the company's entire market capitalization coming directly from executive conviction. This aggressive insider buying is a critical counter-signal against a challenging financial backdrop, including a going concern warning and an existing $100M At-The-Market offering from April. Yet, it follows closely on the heels of the initial purchase orders for a $125 million U.S. program we flagged earlier this month. The CEO is putting serious personal funds on the line, suggesting a deep belief that recent operational developments are significant and the market is missing the true value. When leadership bets this big, especially after prior insider activity, it's a strong indication of perceived undervaluation. We peeled this insight directly from the filing. Headlines are late. Filings aren't. Source & full breakdown: Wiseek (link in bio)

$SMMT — A Co-CEO just dropped $50 million on his own stock. This isn't a typical insider buy. Robert W. Duggan, Co-CEO of SMMT, executed a massive open-market purchase, acquiring shares at $13.11. This single transaction alone represents approximately 0.49% of the company's entire market capitalization and dwarfs his prior open market buys. We've been flagging insider accumulation in SMMT, but this takes conviction to another level. The timing is critical. This mega-purchase comes with SMMT stock trading near its 52-week low, directly after the company *withdrew* its $500 million public offering. Combined with recent positive Phase III data for ivonescimab, this signals a major shift. The cancellation of the offering, followed by such a substantial personal investment, implies strong confidence in the company's existing capital position and future prospects, perhaps without the need for dilutive financing. We peeled this filing. This isn't just a vote of confidence; it's a statement. Most won't catch this until it's priced in. Source & full breakdown: Wiseek (link in bio)

$ALF — The SPAC ALF just secured critical non-redemption agreements for 4.675 million Class A ordinary shares. This move is directly aimed at ensuring the business combination deadline extension passes and keeping cash in the trust. We flagged the "going concern" warning in their last 10-Q. This 8-K shows Centurion Acquisition is fighting to survive. The sponsor is transferring 1.558 million Class A ordinary shares to these investors as an incentive. This agreement prevents a significant portion of shares from being redeemed, which was a major hurdle for the upcoming Extraordinary General Meeting. It solidifies votes needed for the extension, which was previously postponed. With these shares locked, the path for ALF to extend its life appears far clearer. This filing is a direct response to their precarious financial position. Watch for the extension vote results, then focus shifts to their actual business combination. This avoids immediate liquidation. Headlines are late. Filings aren't. Source & full breakdown: Wiseek (link in bio)

$IEHC — IEH Corp doubled its backlog to $27.78 million for the fiscal year ending March 31, 2026. This is a substantial gain, pointing to strong future revenue potential from defense and commercial aerospace orders. This reported figure builds on the *already flagged* record $38M backlog we saw announced just days prior in an 8-K, which projected robust $36M revenue for FY2027. We caught this momentum early. Despite the strong order book, the company shifted to a net loss of $1.30 million, alongside negative operating cash flow of $631,130 for the year. This reflects increased raw material and labor costs outpacing modest revenue growth. We peeled this trend; the last 10-Q already signaled a widening net loss. The material weakness in internal controls also persists, flagged previously, and remains a governance concern. A recent waiver of a debt covenant breach points to financial tightness, though it prevents immediate default. On a positive note, the SEC administrative proceeding was formally dismissed, resolving a long-standing legal overhang. Going forward, traders should monitor going concern language, debt covenant compliance, and any future share count changes or guidance updates. Headlines are late. Filings aren't. Source & full breakdown: Wiseek (link in bio)